二次突变作为BRCA2突变癌症中西斯普拉丁耐药性的机制
Wataru Sakai1, Elizabeth M Swisher, Beth Y Karlan
1Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109-1024, USA.
在BRCA2中发生的二次突变可能会导致BRCA2突变癌症对西斯普拉丁化疗产生抗性. 这些BRCA2基因突变恢复正常功能,导致对类药物和PARP抑制剂的耐药性.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 分子生物学分子生物学
背景情况:
- 在卵巢癌中,BRCA2突变会对基化疗产生敏感性.
- 在这些癌症中,获得的对西斯普拉丁的耐药性是一个重要的临床挑战.
- 在BRCA2突变的癌症中,基底的青抗性的分子机制在很大程度上是未知的.
研究的目的:
- 研究BRCA2突变癌症中获得的西斯普拉丁耐药性的机制.
- 为了确定介导对化合物耐药性的遗传变化.
主要方法:
- 使用了抗思丁的BRCA2突变乳腺癌和胰腺癌细胞系 (HCC1428,Capan-1).
- 应用西斯选择来诱导耐药性,并分析了BRCA2.2中的二次突变.
- 评估对西斯丁和聚基酸聚合酶 (PARP) 抑制剂AG14361.1的耐药性.
- 从接受西斯普拉丁治疗的患者中检查了复发性卵巢瘤.
主要成果:
- 确定了可恢复野生类型读取框架和BRCA2功能的二次内基因BRCA2突变.
- 证明这些二次突变赋予了对西斯普拉丁和PARP抑制剂的耐药性.
- 观察到BRCA2突变的逆转在患者的复发性晶抗性卵巢瘤中.
结论:
- 修复BRCA2读取框架的二次突变是获得西斯普拉丁耐药性的关键机制.
- 这种机制有助于BRCA2突变癌症中对基化疗的临床耐药性.
- 了解这种抗药性途径可能会为未来的治疗策略提供信息.
更多相关视频
08:53Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
相关概念视频
Treatment Resistant Cancers
Cancers Originate from Somatic Mutations in a Single Cell
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
